Dr. Desai on Immune Checkpoint Inhibitors with Chemoradiation in Urothelial Cancer
Neil Desai, MD, discusses the investigation of immune checkpoint inhibitors with chemoradiation in urothelial cancer.
Dr. Desai on the Ideal Patient for Bladder Preservation in Urothelial Cancer
Neil Desai, MD, discusses the ideal patient for bladder preservation in urothelial cancer.
Dr. Desai on the Evolving Standard of Care in Urothelial Cancer
Neil Desai, MD, discusses the evolving standard of care in urothelial cancer.
Dr. Desai on Expanding Options for Cisplatin-Ineligible Bladder Cancer
Neil Desai, MD, discusses the variety of options available for patients with localized urothelial cancer who are ineligible for cisplatin-based chemoradiation.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
2 Clarke Drive Cranbury, NJ 08512